Boston, MA, United States of America

Stuart B Levy

This inventor holds 34 USPTO granted patents and 16 published patent applications and 2 EPO patents, primarily in Tetracycline Compounds. Top assignees: Tufts University, Paratek Pharmaceuticals, Inc., Boston University. Active years: 1989-2017.

USPTO Granted Patents = 34 

% Patents Active = 52.9

 

Average Co-Inventor Count = 1.6

ph-index = 12

Forward Citations = 530(Granted Patents)


Company Filing History:


Years Active: 1989-2017

Loading Chart...
Loading Chart...
Areas of Expertise:
Tetracycline Compounds
RNA Modulation
Spinal Muscular Atrophy
Microbial Resistance
Antibiotic Resistance
Polypeptide Binding
Cryptosporidium Parvum
Oligonucleotides
Bacterial Tolerance
Doxycycline
Sancycline
MarR Family
34 patents (USPTO):Explore Patents

Title: Innovations and Contributions of Stuart B. Levy in Biotechnology

Introduction: Stuart B. Levy, based in Boston, MA, is a distinguished inventor and researcher in the field of biotechnology, particularly known for his work with tetracycline compounds. With an impressive portfolio of 34 patents, Levy has significantly advanced our understanding of RNA modulation and the treatment of various diseases, including spinal muscular atrophy.

Latest Patents: Among his recent innovations, Levy has developed methods for using substituted tetracycline compounds to modulate RNA. This groundbreaking approach describes a novel technique for influencing RNA activity, which could have implications for numerous therapeutic applications. Additionally, he has outlined methods for treating spinal muscular atrophy using these tetracycline compounds, providing new insights into treatment avenues for this challenging condition.

Career Highlights: Throughout his career, Levy has made significant contributions through his association with prestigious institutions like Tufts College and Paratek Pharmaceuticals, Inc. His research has not only enhanced academic knowledge but has also translated into practical applications that benefit the health sector.

Collaborations: Levy has collaborated with notable colleagues, including Mark L. Nelson and Todd Bowser. These partnerships have enabled him to expand his research scope and impact within the biotechnology community.

Conclusion: Stuart B. Levy’s inventive spirit and dedication to research are evident in his impressive patent portfolio and collaborative efforts. His work with tetracycline compounds marks a significant advancement in biotechnology, showcasing the potential of innovative approaches in addressing complex medical challenges.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to [email protected]
Loading…